Exploiting Epigenetic Alterations in Prostate Cancer
AbstractProstate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant activity of enzymes and reader proteins involved in these epigenetic processes, leading to the search for dedicated inhibitory compounds. In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. In addition, the assessment of microRNAs as stratification biomarkers, and early clinical trials evaluating suppressor microRNAs as potential prostate cancer treatment are being discussed. View Full-Text
Share & Cite This Article
Baumgart, S.J.; Haendler, B. Exploiting Epigenetic Alterations in Prostate Cancer. Int. J. Mol. Sci. 2017, 18, 1017.
Baumgart SJ, Haendler B. Exploiting Epigenetic Alterations in Prostate Cancer. International Journal of Molecular Sciences. 2017; 18(5):1017.Chicago/Turabian Style
Baumgart, Simon J.; Haendler, Bernard. 2017. "Exploiting Epigenetic Alterations in Prostate Cancer." Int. J. Mol. Sci. 18, no. 5: 1017.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.